3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Conditions
Neoplasms
1905
Breast Neoplasms
1426
Carcinoma, Non-Small-Cell Lung
1179
Prostatic Neoplasms
740
Colorectal Neoplasms
686
Neoplasm Metastasis
624
Multiple Myeloma
548
Melanoma
529
Ovarian Neoplasms
456
Lung Neoplasms
447
Lymphoma, Non-Hodgkin
385
Recurrence
374
Lymphoma
374
Leukemia, Myeloid, Acute
370
Pancreatic Neoplasms
358
Carcinoma, Renal Cell
339
Carcinoma, Hepatocellular
286
Stomach Neoplasms
281
Leukemia, Lymphocytic, Chronic, B-Cell
268
Lymphoma, Follicular
254
Head and Neck Neoplasms
246
Glioblastoma
220
Leukemia
215
Small Cell Lung Carcinoma
183
Lymphoma, Large B-Cell, Diffuse
183
Squamous Cell Carcinoma of Head and Neck
181
Urinary Bladder Neoplasms
175
Carcinoma
175
Uterine Cervical Neoplasms
174
Advanced Solid Tumors
161
Interventions
pembrolizumab
2
Platinum
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Solid Neoplasms
×
Clear all
NCT04420884
2026-04-08
iintune-1
Takeda
Phase 1/2
Completed
248 enrolled
NCT03364049
2021-11-15
MK-7162-002
Merck Sharp & Dohme LLC
Phase 1
Completed
33 enrolled
19 charts